These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6346614)

  • 1. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity.
    Gratwohl A; Speck B; Wenk M; Forster I; Müller M; Osterwalder B; Nissen C; Follath F
    Transplantation; 1983 Jul; 36(1):40-4. PubMed ID: 6346614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
    Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporin A serum and blood levels in marrow graft recipients: correlation with administered dose, serum creatinine and graft-versus-host disease.
    Bacigalupo A; Di Giorgio F; Frassoni F; Van Lint MT; Raffo MR; Gogioso L; Viale M; Marmont AM
    Acta Haematol; 1984; 72(3):155-62. PubMed ID: 6438979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation].
    Matsushita T; Akatsuka Y; Towatari M; Takeyama K; Miyamura K; Sugihara T; Minami S; Kodera Y
    Rinsho Ketsueki; 1989 Apr; 30(4):429-36. PubMed ID: 2671437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation.
    Yee GC; Self SG; McGuire TR; Carlin J; Sanders JE; Deeg HJ
    N Engl J Med; 1988 Jul; 319(2):65-70. PubMed ID: 3288872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation.
    Ghalie R; Fitzsimmons WE; Weinstein A; Manson S; Kaizer H
    Ann Pharmacother; 1994 Mar; 28(3):379-83. PubMed ID: 8193430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D; Shapiro S; Schwinghammer TL; Bloom EJ; Rosenfeld CS; Shadduck RK; Venkataramanan R
    Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciclosporin A: correlation of blood levels with acute graft-versus-host disease after bone marrow transplantation.
    Bandini G; Strocchi E; Ricci P; Rizzi S; Boschi S; Guardigli C; Calori E; Motta MR; Giudice V; Rosti G
    Acta Haematol; 1987; 78(1):6-12. PubMed ID: 3116813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation.
    Schmidt H; Ehninger G; Dopfer R; Blaurock M; Naumann R; Einsele H; Haen M; Schüch K; Jaschonek K; Niethammer D
    Blut; 1988 Sep; 57(3):139-42. PubMed ID: 3046689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation.
    Abedi MR; Bäckman L; Boström L; Lindbäck B; Ringdén O
    Bone Marrow Transplant; 1990 Aug; 6(2):121-6. PubMed ID: 2207449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors.
    Nawa Y; Hara M; Tanimoto K; Nakase K; Kozuka T; Maeda Y
    Int J Hematol; 2006 Feb; 83(2):159-63. PubMed ID: 16513536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease.
    Miralbell R; Bieri S; Mermillod B; Helg C; Sancho G; Pastoors B; Keller A; Kurtz JM; Chapuis B
    J Clin Oncol; 1996 Feb; 14(2):579-85. PubMed ID: 8636774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months.
    Yee GC; McGuire TR; St Pierre BA; Self SG; Zager RA; Sullivan KM; Deeg HJ
    Bone Marrow Transplant; 1989 Nov; 4(6):691-4. PubMed ID: 2684309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients.
    Lindholm A; Ringdén O; Lönnqvist B
    Transplantation; 1987 May; 43(5):680-4. PubMed ID: 3554661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
    Truog AW; Wozniak SP
    Oncol Nurs Forum; 1990; 17(1):39-44. PubMed ID: 2405360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients.
    Dieterle A; Gratwohl A; Nizze H; Huser B; Mihatsch MJ; Thiel G; Tichelli A; Signer E; Nissen C; Speck B
    Transplantation; 1990 Jun; 49(6):1093-100. PubMed ID: 2193442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic reactivity in marrow graft recipients receiving cyclosporine to prevent graft-versus-host disease.
    Von Fliedner VE; Jeannet M; Gratwohl A; Pongratz G; Neri C; Nissen C; Muller M; Osterwalder B; Speck B
    Transplantation; 1983 Aug; 36(2):125-30. PubMed ID: 6349034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.